par
Gus Iversen, Editor in Chief | December 15, 2025
Telix Pharmaceuticals and Varian, a Siemens Healthineers company, have announced a clinical collaboration aimed at combining radiopharmaceutical theranostics with external beam radiation therapy (EBRT).
The agreement will support joint and investigator-led studies, starting with prostate cancer, to evaluate how molecular imaging can enhance patient selection and treatment planning in radiation oncology.
The Melbourne-based radiopharmaceutical developer and the Palo Alto, California-based radiation therapy company plan to explore the use of Telix’s PSMA-PET imaging agents, Illuccix and Gozellix, in EBRT workflows. One area of investigation includes the integration of these imaging tools into Varian’s Ethos adaptive radiotherapy platform to support personalized treatment plans and monitor therapeutic response.
Ad Statistics
Times Displayed: 344592
Times Visited: 21056 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
According to the companies, the collaboration could enable radiation oncologists to more precisely tailor treatments by using PET imaging to identify patients likely to benefit from targeted radiotherapy. “Collaborating with Telix opens a powerful pathway to embed precision imaging and theranostics into the radiation therapy workflow,” said Dr. Arthur Kaindl, head of Varian.
While the initial focus is on prostate cancer, the agreement establishes a framework for broader codevelopment efforts. Telix’s pipeline includes other diagnostic agents, such as TLX250-CDx (Zircaix) for renal cell carcinoma and TLX101-CDx (Pixclara) for brain cancer, which may also be studied under the partnership. Future applications may include therapeutic radiopharmaceuticals.
Dr. Christian Behrenbruch, group CEO and managing director of Telix, said the collaboration represents “a transformative opportunity to bring precision imaging into the heart of radiation oncology.”
EBRT remains a central modality for managing solid tumors, but the potential to pair it with radiopharmaceutical diagnostics and therapeutics could expand its utility in both curative and palliative settings. The companies have not disclosed timelines for the clinical studies.
